MDxHealth SA (MDXH)
- Globe Newswire
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk
- Insider Monkey
MDxHealth SA (NASDAQ:MDXH) Q4 2023 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH) Q4 2023 Earnings Call Transcript March 6, 2024 MDxHealth SA misses on earnings expectations. Reported EPS is $-0.39 EPS, expectations were $-0.28. MDXH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen and […]
- GlobeNewswire
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42%2023 gross margin expanded by 10.7 percentage points over prior yearConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth
